The Zacks Analyst Blog Highlights: InterMune, Kite Pharma, Amicus, Celgene and Bristol-Myers Squibb


For Immediate Release
Chicago, IL – August 28, 2014 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the InterMune (ITMN-Free Report), Kite Pharma (KITE-Free Report), Amicus (FOLD-Free Report), Celgene (CELG-Free Report)  and Bristol-Myers Squibb (BMY-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Biotech Stock Roundup
The biotech sector had a strong run last week thanks mostly to Roche’s agreement to acquire InterMune (ITMN-Free Report) for a hefty $8.3 billion. The announcement of this deal resulted in a spike in the share price of quite a few mid-cap biotech companies that are considered to be lucrative acquisition targets.
Recap of the Week’s Most Important Stories
1. The week’s most important news was the $8.3 billion agreement announced by Roche for the acquisition of InterMune (read more: Roche to Boost Respiratory Product Lineup with InterMune Buy). This deal has raised hopes for several other mid-cap biotech companies which have some lucrative candidates in their pipeline. Smaller biotechs have recently touched 52-week highs, some of which may be considered attractive takeover targets. With the biotech sector witnessing a lot of M&A activity so far this year, expectations are high that more such deals will follow (Read more: 3 Biotechs Surging Following InterMune Takeover).
2. Kite Pharma’s (KITE-Free Report) shares shot up 17.7% on positive data from a non-Hodgkin's lymphoma study on KTE-C19. The data looks good though Kite is still several years from bringing this product to market. The data was from a phase I-IIa study and Kite intends to file an investigation new drug application later this year for a phase I-II single-arm multicenter study. This study will commence in the first half of 2015 (read more: Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study).
3. Amicus’ (FOLD-Free Report) shares jumped 20.4% with the company reporting positive data on its experimental Fabry disease treatment, migalastat. Although treatments for this rare inherited disease are already available, migalastat’s oral dosing regimen could prove to be a more convenient treatment option for patients.
4. Immuno-oncology continues to be a target area. Celgene (CELG-Free Report) is collaborating with Bristol-Myers Squibb (BMY-Free Report) for the evaluation of a combination treatment comprising Bristol-Myers’ investigational PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), and Celgene’s nab technology-based chemotherapy Abraxane. The combination will be studied for different types of cancer (read more: Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on ITMN - FREE
Get the full Report on KITE - FREE
Get the full Report on FOLD - FREE
Get the full Report on CELG - FREE
Get the full Report on BMY - FREE
Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Read the analyst report on ITMN

Read the analyst report on KITE

Read the analyst report on FOLD

Read the analyst report on CELG

Read the analyst report on BMY

Zacks Investment Research

View Comments (0)